2 results
Approved WMORecruiting
The main objective of this study is to determine how well the Multiple Screener© can differentiate between patients with no cognitive deficits, mild cognitive deficits and cognitive impairment. Additionally, we aim to confirm the observed accuracy…
Approved WMORecruiting
Primary:To determine the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) of MK-5890 when used as monotherapy and in combination with pembrolizumab in the dose escalation and confirmation phase and the dose…